AXL and neoplasm: GL21.T, a selective RNA-based aptamer, bound to the ectodomain regions of AXL (Kd = 12 nM) and reduced catalytic activity and AXL-dependent signaling, inhibited cellular migration and invasion, and reduced NSCLC tumor volume by 68.2% in vivo [255,275].